SciELO - Scientific Electronic Library Online

 
vol.35 número4Manejo de la hipertensión arterial en el adulto mayorTrombosis venosa cerebral: lo que hay que saber índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Servicios Personalizados

Revista

Articulo

Indicadores

Links relacionados

  • No hay artículos similaresSimilares en SciELO

Compartir


Medicina interna de México

versión impresa ISSN 0186-4866

Resumen

MELLADO-ORELLANA, Raúl et al. Pharmacological treatment of diabetes mellitus type 2 directed to patients with overweight and obesity. Med. interna Méx. [online]. 2019, vol.35, n.4, pp.525-536.  Epub 26-Mar-2021. ISSN 0186-4866.  https://doi.org/10.24245/mim.v35i4.2486.

Diabetes mellitus type 2 (DM2) is a chronic and multifactorial disease that requires an integral treatment throughout the life of the patient and in need of constant adjustments according to specific requirements of each patient. It is well established that weight loss in diabetic patients may delay the progression of the disease or even delay its onset. In addition to being a beneficial factor in the treatment goals of diabetic patients, weight reduction can achieve clinically significant changes in serum glucose, glycated hemoglobin (HbA1c) and triglyceride levels. Evidence-based recommendations are currently aimed at pharmacological, surgical and lifestyle changes in the management of obesity as part of the comprehensive treatment of patients with diabetes mellitus type 2. Traditional pharmacological treatments for diabetes mellitus type 2 may further increase weight and this may decrease the benefits of adequate glycemic control. It’s important to identify the interference of each drug group on weight.

Palabras llave : Diabetes mellitus type 2; Weight loss; Glycated hemoglobin; Obesity.

        · resumen en Español     · texto en Español     · Español ( pdf )